Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
Can your cat recognise you by scent? New study shows it’s likely 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Dollar Strengthens as U.S.-Iran Peace Talks Send Mixed Signals 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
